Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...